MET and neoplasm: Noteworthy, despite the cutoff to define MET positivity with immunohistochemistry was the same between phase II and III (expression ≥1+ in ≥25% of tumor cells), there was a relevant difference in the number of patients screened who were considered MET positive in phase II (64%) and phase III (81%) trial, for not known reasons.